Skip to Main Content

Cancer drug developer Innovent Biologics started an early-stage clinical trial for its monoclonal antibody IBI939, the first anti-TIGIT drug to be tested in China.

The Suzhou biotech is hoping to develop the antibody into a potential treatment for advanced forms of cancer, either as a monotherapy or in combination with Tyvyt, its approved PD-1 drug for Hodgkin’s lymphoma.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!